Partner Headlines - FOLD

  1. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  2. Morning Market Gainers

    Benzinga
  3. Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday ...

    Benzinga
  4. Benzinga's Top #PreMarket Gainers

    Benzinga
  5. NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report

    Benzinga
  6. These 4 Biotech Stocks Have Been On Fire

    Benzinga
  7. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  8. Benzinga's Top #PreMarket Losers

    Benzinga
  9. Mid-Day Losers From November 18: Omega Protein, Urban Outfitters, ...

    Benzinga
  10. Mid-Afternoon Market Update: Tyson Rises After Q4 Results; DreamWorks ...

    Benzinga
  11. Mid-Day Market Update: Allergan Jumps On Actavis Bid; Denbury ...

    Benzinga
  12. Midday Gainers From November 17: Celldex Therapeutics, Amicus ...

    Benzinga
  13. Mid-Morning Market Update: Markets Edge Lower; Halliburton To ...

    Benzinga
  14. Morning Market Movers

    Benzinga
  15. Benzinga's Top #PreMarket Gainers

    Benzinga
  16. Top 5 Biotech Stocks Over The Past Year

    Benzinga
  17. 3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, ...

    Benzinga
  18. Top 5 Performing Biotech Stocks Of 2014

    Benzinga
  19. Morning Market Movers

    Benzinga
  20. The Biotech Stock With The Best One-Week Performance

    Benzinga
  21. Stocks Hitting 52-Week Highs

    Benzinga
  22. Morning Market Movers

    Benzinga
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. Morning Market Movers

    Benzinga
  25. Amicus Extending Rally On Upgrades

    Benzinga
  26. Benzinga's Top Upgrades

    Benzinga
  27. Benzinga's Top #PreMarket Gainers

    Benzinga
  28. Morning Market Movers

    Benzinga
  29. Benzinga's Top #PreMarket Gainers

    Benzinga
  30. Earnings Scheduled For March 3, 2014

    Benzinga
  31. UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious ...

    Benzinga
  32. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  33. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  34. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  35. Amicus, Biogen Announce Deal for Discovery, Development, Commercialization ...

    Benzinga
  36. Amicus Therapeutics Says Added 6-Month Results from Phase 3 Fabry ...

    Benzinga
  37. Amicus Therapeutics Advances Chaperone-ERT Combo Platform in ...

    Benzinga
  38. Amicus Announces Positive Phase 2 Results for Chaperone-Enzyme ...

    Benzinga
  39. Stocks Hitting 52-Week Lows

    Benzinga
  40. UPDATE: Wedbush Downgrades Amicus Therapeutics to Underperform ...

    Benzinga
  41. Option Traders Call a Bottom for Amicus Therapeutics

    SchaeffersResearch
  42. GlaxoSmithKline

    IBD
  43. Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period ...

    Benzinga
  44. Amicus Therapeutics Announces Additional Preliminary Results ...

    Benzinga
  45. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  46. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  47. UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus ...

    Benzinga
  48. Amylin Pharmaceuticals, Best Buy Among Stocks Up on High Volume ...

    FoxBusiness
  49. Benzinga's Top Upgrades with Color for May 8, 2012

    Benzinga
  50. UPDATE: J.P. Morgan Upgrades Amicus Therapeutics

    Benzinga
  51. From Earlier: Amicus Therapeutics Prices Underwritten Offering ...

    Benzinga
  52. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-K)

    GuruFocus
  53. Amicus Therapeutics Presents Preclinical Studies of Chaperone ...

    Benzinga
  54. Amicus Therapeutics Announces Positive Preliminary Results From ...

    Benzinga
Trading Center